Figure 5.

ABT 317 reduces the proportion of effector and memory CD8⁺ T cells in vivo. (A–C): The percentage of KLRG1⁺ T cells in spleen from 13-week-old NOD mice treated with vehicle or 10 mg/kg ABT 317 for 3 weeks. (A) Representative flow cytometry plot and (B) pooled data from n = 9 individual mice for KLRG1⁺CD8⁺ T cells. (C) Pooled data from n = 9 individual mice for KLRG1⁺CD4⁺ T cells. (D–F): (D) Representative flow cytometry plots, (E) the percentage of CD44^hiCD62L^loCD8⁺ T cells and (F) the percentage of CD44^loCD62L^hiCD8⁺ T cells in the spleen from 15–16-week-old NOD mice treated with vehicle or 10 mg/kg ABT 317 for 3 weeks. (G–I): (G) Representative flow cytometry plots, (H) the percentage of CD44^hiCD62L^loCD4⁺ T cells and (I) the percentage of CD44^loCD62L^hiCD4⁺ T cells in the spleen from 13-week-old NOD mice treated with vehicle or 10 mg/kg ABT 317 for 3 weeks. Pooled data are from n = 9 individual mice with the mean ± SEM. Statistical significance: (B): *P = 0.0234, (C): *P = 0.0140, (E): *P = 0.0156, (F): *P = 0.0106, NS, not significant. Student t test.